PUK16 Cost and Cost-Effectiveness of Treating Urgency Stress Incontinence-Results from a Randomized Controlled Trial  by Kafri, R et al.
A632  VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  
1Shahid Beheshti University of Medical Sciences, Tehran, Iran, 2Tehran University of Medical 
Sciences, Tehran, Iran
Objectives: The primary aim of the study was to estimate costs of treatment for the 
first year after renal transplantation from the perspective of health insurance organi-
zations in Iran. MethOds: An Excel-based and a Monte Carlo model were developed 
to determine the treatment costs of current clinical practice in renal transplantation 
therapy (RTT). Inputs were derived from Ministry of Health and insurance organiza-
tions’ database, hospital and pharmacy records, clinical trials and local and interna-
tional literature. According to the model, there were almost 17,000 patients receiving 
RTT in Iran, out of which about 2,200 patients underwent the operation within the 
study year (2011- 2012; n= 2200). Results: The estimated first year total treatment 
cost after renal transplantation was almost $14,000,000. These costs corresponded to 
annual total cost per patient of almost $6500 for the payers. cOnclusiOns: Renal 
transplantation therapy is almost fully reimbursed by government in Iran. However, 
regarding new expensive medicines, cost of medical expenditure is rapidly growing 
and becoming quite unaffordable for the government; therefore, out-of-pocket (OOP) 
payments are dramatically increasing over time. In order to improve reimbursement 
policy making under pressure of current budget constraints, the present study is 
providing decision makers with practical tools make them possible to easily compare 
budgetary impact of the current therapy strategy with the future financial conse-
quences of purchasing newly proposed medicines. In other words having estimation 
of the current budget spending on RTT would help policy makers in making efficient 
resource allocation and decrease quite high OOP expenditures.
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Objectives: To evaluate resource utilisation for subjects with overactive 
bladder (OAB) syndrome who are managed with the commonly prescribed oral 
medications: solifenacin succinate, tolterodine tartrate, or trospium chloride from 
the payer perspective. MethOds: Data were abstracted from medical records for 
qualified subjects who were ≥ 18 years, with a diagnosis for OAB (at least one of the 
following: urgency, frequency with or without urgency incontinence) on or before 
December 31, 2010. Subjects must have been on one of the study medications for at 
least 3 months and have at least 12 months of medical records available. The study 
was approved by local ethics committees and all data provided was anonymised. 
Medication costs for Germany are reported for 2013 € . Results: A total of 136 of 
229 subjects were included for the German analysis. The remaining subjects were 
from the Czech Republic to be reported elsewhere. Top 3 reasons for exclusion from 
Germany include: primary diagnosis of urinary tract infection, urologic surgery 
within 6 months of the data collection, and diabetic neuropathy. The annual overall 
mean cost for office visits, specialist visits, investigations, other treatments, medica-
tions and incontinence pad use with solifenacin (5,10mg/day) (N= 60), trospium (IR 
and ER maximum dose of 60mg/day) (N= 51), and tolterodine (IR 2, 4mg/day and ER 
4mg/day) (N= 25), were € 1,059.31, € 1,247.76, and € 1,626.01, respectively. Incontinence 
pad use for weekly frequency with solifenacin, trospium, and tolterodine was, 17.34, 
19.51 and 20.35, respectively. Overall satisfaction with medication as perceived by 
the clinician (very satisfied, satisfied, neutral, dissatisfied, very dissatisfied) for very 
satisfied and satisfied was 97%, 86%, 100%, for solifenacin, trospium, tolterodine, 
respectively. cOnclusiOns: Solifenacin had the lowest annual cost-in-use com-
pared to other study drug annual cost. This was corroborated in part by the lowest 
incontinence pad use for solifenacin compared to trospium and tolterodine and 
the high treatment satisfaction.
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Objectives: Urgency urinary incontinence (UUI) has a substantial impact on 
patients’ QOL and well-being, and may pose a substantial economic burden on 
patients and health insurers. We assessed the cost and cost-effectiveness of four 
conservative treatment modalities for UUI in Israel. MethOds: A total of 164 
women were randomly allocated to one of four interventions: drug therapy (DT), 
bladder training (BT), pelvic floor muscle-training (PFMT), and combined pelvic floor 
rehabilitation (CPFR) and were followed over a period of 12-months. Resource utili-
zation including physician encounters, dispensed prescriptions, physical therapist 
treatment and any other medical services was estimated for each study participant. 
We also estimated the women’s self-reported utilizations of pads, laundry and new 
underwear. Total costs were calculated by multiplying the volumes of resource uti-
lization by the corresponding unit-prices. We used the bootstrap method to report 
bias-corrected confidence-intervals of cost estimates. Utility weights were elicited 
using the EQ-5D questionnaire at baseline, 3-months and 12-months of follow-
up. Results: Women in all four treatment groups showed improvements in QOL 
from baseline to 12-months (DT:0.87 - 0.93, BT:0.85 to 0.89, PFMT:0.82 - 0.84, CPFR: 
0.82 to 0.86). Changes in QOL summary scores from study enrollment and end of 
follow-up were estimated after correction for potential baseline differences, and 
were not statistically different among study groups. The mean total cost was some-
what lower for the DT group participants ($1,460), as compared with the three other 
interventions (range: $1,760-$1,990). These differences, however, were not statisti-
cally significant. The mean monthly personal costs were significantly reduced from 
baseline to 12-months of follow-up in all treatment groups. cOnclusiOns: The 
four treatment modalities for treating UUI were equally effective and associated 
of hospitalizations with ICD-9 diagnosis codes of CKD and End Stage Renal Disease 
(ESRD). The annual number of hospitalizations for specific diagnosis was obtained 
from AHRQ’s National In-patient Sample (NIS) databases of 2005-2009. Data was 
also analyzed for length of stay (LOS), charges and cost of hospitalization. Results: 
During the last five years the number of hospitalizations with diagnosis of CKD and 
ESRD has increased 4.1 and 4.6 fold, respectively. In 2009, an estimated 1,634,422 
and 931,641 hospitalizations were with diagnosis of CKD and ESRD respectively. The 
mean LOS for patients with CKD increased from 4.9 to 5.5 days between2005-2009. 
The mean LOS for patients with ESRD has remained steady at ~6 days between 2005-
2009. The cost of hospitalization with diagnosis of CKD has increased 31% between 
2005-2009. The cost of hospitalization with diagnosis of ESRD has increased 21% 
between 2005-2009. In 2009, the mean cost of hospitalization for patients with CKD 
and ESRD was $11,209 and $21,358, respectively. cOnclusiOns: Hospitalizations 
due to CKD and ESRD have significantly increased during the last five years. There 
is a need for prevention, treatment, and disease management programs to lower 
the medical and socioeconomic burden of this disease.
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Objectives: To examine the economic burden and health care utilizations of 
patients diagnosed with chronic kidney disease (CKD) in the U.S. veteran popula-
tion. MethOds: A retrospective database analysis was performed using the Veterans 
Health Administration (VHA) Medical SAS datasets (01OCT2008-30SEP2012). Patients 
diagnosed with CKD were identified using International Classification of Disease 9th 
Revision Clinical Modification (ICD-9-CM) diagnosis codes 585.xx, 250.4xx, 791.0x, 583.
xx, and 403.xx. The first diagnosis date was designated as the index date. A group of 
non-CKD patients of the same age, region, gender and index year were identified and 
matched on baseline Charlson Comorbidity Index (CCI) as the comparison group with 
a randomly chosen index date to minimize selection bias. Patients in both groups 
were required to be at least 18 years old, and have continuous health plan benefits 
1 year before and 1 year after the index date. One-to-one propensity score match-
ing was used to compare the health care costs and utilizations during the follow-up 
period between the CKD and comparison groups, adjusted for baseline demographic 
and clinical characteristics. Results: A total of 477,078 patients were identified for 
the CKD cohort and the comparison cohort. After 1:1 matching, 155,324 of patients 
were matched from each group, and the baseline characteristics were well-balanced. 
CKD Patients incurred higher health care utilizations in inpatient (17.00% vs. 2.84%, 
p< 0.01), emergency room (17.81% vs. 6.64%, p< 0.01), physician office (99.28% vs. 67.92%, 
p< 0.01), outpatient (99.36% vs. 68.69%, p< 0.01), and pharmacy visits (91.16% vs. 72.61%, 
p< 0.01). The CKD group also had higher patient expenditures in inpatient ($6,228 vs. 
$802, p< 0.01), emergency room ($194 vs. $62, p< 0.01), physician office ($3,287 vs. $1,516, 
p< 0.01), outpatient ($3,788 vs. $1,715) and pharmacy ($848 vs. $490, p< 0.01) than 
patients in the comparison group. cOnclusiOns: CKD patients had a significantly 
higher burden of illness compared to a similar comparison group of non-CKD patients.
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Objectives: Itchy and dry skin, symptoms of pruritus, are commonly reported by 
patients with end-stage renal disease (ESRD). Previous analyses of a large dialysis 
organization (LDO) suggested that these symptoms are associated with decreased 
quality of life and poorer health outcomes. As a result, these patients may represent 
a higher economic burden to payers. This retrospective cohort study compared direct 
health care resource utilization (HRU) and costs associated with varying degrees of 
self-reported itchiness/dryness skin severity. MethOds: Adult patient data (≥ 18 
years old) from the 2009 United States Renal Disease System (USRDS) dataset were 
combined with corresponding Kidney Disease Quality of Life (KDQOL) survey data 
obtained between January to September 2009, at an LDO. Patients were included if 
they had answered KDQOL itchiness/dryness questions, had KDQOL assessments ≥ 
3 months after starting dialysis, and had Medicare as their primary payer. Patients 
were grouped by their itchiness/dryness severity. All HRU and cost outcomes were 
described over a 3-6 month follow-up period post-KDQOL survey. Patients were 
censored for death, transplant, change in treatment modality, discontinued treat-
ment, or loss of observation during the follow-up period. Results: Study popula-
tion included 1,387 patients. HRU analyses of itchiness showed increased rate of 
hospitalizations (42.5% vs. 28.4%) for patients who were extremely bothered versus 
not bothered by itch. Similar results were observed for dryness (34.3% vs. 27.5%) 
and combined itchiness and dryness (34.2% vs. 28.0%). Extremely bothered patients 
had higher overall health care costs: $33,755 vs. $26,933 for itchiness; $29,801 versus 
$26,321 for dryness; and $29,249 vs. $26,736 for combined itchiness and dryness. 
Dialysis and hospitalization costs contributed the most toward overall health care 
costs. cOnclusiOns: These results suggest an association between increased skin 
itchiness/dryness and increased hospitalizations and health care costs. Additional 
research, adjusting for patient characteristics, is needed to provide more evidence 
for the burden of skin itchiness/dryness in ESRD patients.
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and ER tolterodine patients remained on treatment until week 52, respectively. QALYs 
were higher with fesoterodine than tolterodine (0.762 vs. 0.760). In Spain, fesoterodine 
treatment had higher costs than (generic) ER tolterodine (€ 6 697 vs. € 6 597), resulting 
in a cost of € 15 600/QALY gained. In Finland, fesoterodine was cost-saving relative to 
(non-generic) ER tolterodine (€ 7 885 vs. € 8 024). Sensitivity analysis confirmed these 
findings were robust to the expected price decrease for generic ER tolterodine in 
Finland. In the PSA, fesoterodine was consistently the preferred therapy in Finland 
regardless of the value of a QALY and in Spain for QALY valuations greater than 
€ 15 000. cOnclusiOns: Fesoterodine is cost-effective or cost-saving relative to ER 
tolterodine for the treatment of OAB with UUI in two European countries. Payers and 
prescribers should consider a broad scope of costs in order to make informed cost-
conscious choices of antimuscarinic treatment.
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Objectives: Overactive bladder (OAB) is a chronic condition which affects quality 
of life through the main symptoms of urinary urgency, urinary frequency, and uri-
nary incontinence. Treatments include behavioural therapy, antimuscarinics (AM), 
β 3-adrenoceptor agonsits (mirabegron), botulinum toxin (botox) and sacral nerve stimu-
lation (SNS). The aim of this analysis was to evaluate the costs and outcomes associated 
with different sequences of oral treatments (AM and mirabegron). MethOds: A Markov 
model with monthly cycle length and a time horizon up to 3 years compared two dif-
ferent sequences of up to three lines of oral treatments. Patients who discontinue one 
oral medication may switch to another oral medication, or may discontinue treatment. 
Patients whose symptoms are not improved are considered for botox or SNS. Outcomes 
are measured by (a) number of patients with improved symptoms (< 2 incontinence 
episodes and < 8 micturitions per 24-hours); (b) patients with < 2 incontinence epi-
sodes per 24-hours; and (c) patients with < 8 micturitions per 24-hours. Results: 
Including a third-line oral medication before considering other treatment options 
improved all patient outcomes, irrespective of the particular drugs used. A three-line 
sequence including two generics (oxybutynin (1st line), and tolterodine ER (2nd line)), 
and one branded drug (solifenacin 5mg (3rd line)) resulted in inferior patient outcomes 
and higher cost compared with a sequence of branded drugs (mirabegron (1st line), 
solifenacin 5mg (2nd line), solifenacin 10mg (3rd line)): improved patients (70/1000 
vs. 92/1000); patients with < 2 incontinence episodes (181/1000 vs. 217/1000); patients 
with < 8 micturitions (248/1000 vs. 299/1000). Annual treatment costs were higher in 
the generic sequence (£2659 per patient vs. £2479). cOnclusiOns: Low-cost generic 
treatments are not necessarily more cost-effective than branded drugs. The main rea-
son is that a better efficacy and tolerability balance improves symptoms and quality of 
life, leading to better persistence and lower overall treatment costs.
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Objectives: Mirabegron is a first-in-class beta-3 adrenoceptor agonist for the treat-
ment of overactive bladder (OAB) that demonstrated superior efficacy compared to 
placebo in OAB. The cost-effectiveness of mirabegron 50 mg (MGN) was assessed in 
comparison with tolterodine ER 4 mg (TOL) in the UK. MethOds: A Markov model 
was developed to simulate the therapeutic management, the changes in symptoms 
(micturitions and incontinence), and complications in OAB patients. The model was 
used to predict costs and QALYs over 5 years in cohorts initially treated with MGN 
or TOL, followed by antimuscarinics in case of lack of efficacy or adverse events. 
Transition probabilities and EQ-5D utilities were obtained from regression models, 
estimated from a P3 randomized controlled trial of mirabegron. Costs were evalu-
ated from the UK National Health Service (NHS) perspective and included drug 
acquisition, physician visits, pads and botulinum toxin injections. Subgroup analy-
ses were performed for previously treated, treatment naïve, incontinent, female and 
elderly patients. Results: The MGN strategy was more expensive compared to 
TOL, with a difference of £37.88 per patient, and produced more QALYs (+0.009 per 
patient). The incremental cost-effectiveness ratio (ICER) was estimated at £4,386/
QALY gained. Results of one-way sensitivity analyses showed that in all scenarios, 
except one (the transition probabilities between symptom levels of micturition for 
mirabegron), MGN remained cost-effective or was dominant compared to TOL. Key 
cost-effectiveness drivers included parameters related to efficacy and treatment 
discontinuation. Based on the probabilistic sensitivity analysis, the probability of 
MGN being cost-effective against TOL was 89.4% at a threshold of £20,000 per QALY 
gained. ICERs in subgroups ranged from £3,091 (female subgroup) to £5,736 (elderly 
subgroup). cOnclusiOns: Treatment with mirabegron 50 mg appears to be a cost-
effective strategy compared with tolterodine ER 4 mg for the general OAB population 
and the specified subgroups, from a UK NHS perspective.
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with comparable costs. Therefore, an incremental cost-effectiveness ratio was cal-
culated. Due to the possibility of declining adherence to drug therapy over time, 
pelvic floor physical therapy can be considered as the first line treatment for UUI.
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Objectives: Hypertension is a chronic medical condition and an important risk 
factor in several fatal and debilitating diseases. NICE estimates the cost of pharma-
cologic intervention in the UK for hypertension at £409.8 million. Resistant hyper-
tension arises when blood pressure remains uncontrolled despite antihypertensive 
treatment. Renal denervation is a new procedure aimed at reducing blood pressure 
in resistant hypertension patients by decreasing efferent sympathetic signalling to 
the kidneys. The objective of this research was to review the evidence on the cost of 
renal denervation and to provide a costing model for the procedure. MethOds: A 
targeted review of costing data was performed and information gathered from renal 
denervation experts to establish relevant procedure costs. Once specific health care 
resource use (HRU) and equipment costs were identified, an Excel™ costing model 
was constructed. A further search of NHS costing documents, academic literature, 
and expert consultation provided GBP figures for each cost and identified those that 
were time dependent (e.g. hourly staff costs). Results: The required in-patient 
HRU was identified as staff costs per hour including surgeon costs, nurse costs, 
technician costs and anaesthesiologist costs, all of which vary with procedure time 
depending on the device used (ranging from 20-60 minutes). Catheter lab overhead 
costs per hour and recovery costs (bed days) were also identified. Total HRU costs 
vary between £923.02 and £991.62 (for 20 and 60 minute procedure times respec-
tively). An additional in-hospital recovery day adds £680. Equipment costs were for 
12 items including from syringes to catheters to valves, totaling £281.70 plus the 
cost of the renal denervation therapy device. cOnclusiOns: It is essential the 
cost of the procedure is estimated to fully inform payers and health care providers. 
HRU costs are dependent on procedure time and length of recovery in hospital, thus 
devices that reduce these factors are best for cost savings.
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Objectives: Despite significant improvements in survival and quality of life (QoL) 
of liver transplant (LTx) recipients, patients remain at risk from complications 
related to disease recurrence and long-term use of immunosuppressant (IS). The 
objective was to assess cost, survival, and QoL outcomes of LTx recipients and 
the impact of renal dysfunction on LTx outcomes. MethOds: A de novo cohort 
Markov model was developed to predict long-term outcomes post LTx along two 
independent pathways: 1) liver-related (acute rejection, hepatocellular carcinoma, 
hepatitis C (HCV) recurrence, graft loss), 2) kidney-related (chronic kidney disease, 
dialysis, renal transplantation) and death. All patients, stratified by liver diagno-
sis, entered the model at time of LTx and followed both pathways, allowing for 
multiple combinations of liver and kidney health states. Costs and utilities were 
assigned to each health renal and liver state. Renal complications costs and utility 
decrements were added to those accrued in the liver pathway. The lifetime model 
used an annual cycle length except for the 1st year post LTx (quarterly). Choice of 
immunosuppressant strategy could impact the risk of acute rejection, change in 
renal function and HCV fibrosis progression. A 3% discount rate was applied to 
costs and outcomes. Results: On average, life expectancy post LTx was 13.3 years 
with 10.2 QALYs. Lifetime cost of managing post LTx recipients was USD 550,000 
(excluding LTx procedure): > 50% was related to IS regimen, monitoring and adverse 
events; around 40% to renal complications and 2-7% to liver complications. Patients 
developing renal dysfunction lost 5.2 life-years and 1.5 QALYs. cOnclusiOns: To 
our knowledge, this is the first Markov model simulating lifetime costs and out-
comes post-LTx and the impact of change in renal function on patient survival. A 
health care intervention that could improve or maintain renal function would have 
significant impact on survival and costs.
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Objectives: To assess the economic value of fesoterodine compared to tolterodine 
for the treatment of overactive bladder (OAB) with urgency urinary incontinence (UUI) 
in Spain and Finland. MethOds: A decision-tree economic model estimated the 
52-week costs and quality-adjusted life years (QALYs) of OAB/UUI patients initiating 
treatment with fesoterodine 4mg/day or extended-release (ER) tolterodine. Treatment 
response (UUI < 1 episode/day) and persistence were evaluated at weeks 4, 12, and 24. 
Titration from fesoterodine 4mg/day to 8mg/day was permitted at week 4. At week 
12, non-responders discontinued treatment permanently. Efficacy, discontinuation, 
and utility data were derived from four clinical trials of fesoterodine. OAB-related 
costs including physician visits, laboratory tests, incontinence pads, and comorbidi-
ties (fracture, skin infection, urinary tract infections, depression, and nursing home) 
were also included. The perspective was that of the National Health Systems (2012€ ). 
Uncertainty surrounding the model parameters was assessed by univariate and prob-
abilistic sensitivity analysis (PSA). Results: A total of 19.5% and 18.0% of fesoterodine 
